- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 587902, 15 pages
Rokumi-jio-gan-Containing Prescriptions Attenuate Oxidative Stress, Inflammation, and Apoptosis in the Remnant Kidney
1Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan
2Chinese Medicine and Health Food Department, Iskra Industry Co., Ltd., Tokyo 103-0027, Japan
3Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan
4Organization for Promotion of Regional Collaboration, University of Toyama, Toyama 930-8555, Japan
Received 30 July 2012; Revised 9 October 2012; Accepted 12 October 2012
Academic Editor: Cheorl-Ho Kim
Copyright © 2012 Chan Hum Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. E. Mitch and M. Walser, “Nutritional therapy of the uremic patient,” in The Kidney, B. M. Brenner and F. C. Rector, Eds., pp. 1756–1790, Saunders, Philadelphia, USA, 1986.
- K. Kumano, S. Takara, and H. Izumi, “The modification of dietary protein and administration of oral adsorbent AST-120 in chronic renal failure rats,” Japanese Journal of Nephrology, vol. 29, no. 2, pp. 185–194, 1987.
- M. Miyazaki, K. Aoyagi, and S. Tojo, “Lactulose therapy for chronic renal failure,” Japanese Journal of Nephrology, vol. 26, no. 8, pp. 1091–1098, 1984.
- H. Ha, J. K. Lee, H. Y. Lee et al., “Safety evaluation of Yukmijihwang-tang: assessment of acute and subchronic toxicity in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 672136, 8 pages, 2011.
- T. Huang, “Hachimi-jio-gan,” in A Handbook of Traditional Chinese Prescriptions of Dubious and Complicated Cases, pp. 527–538, China Medical and Pharmaceutical Science and Technology Publishing House, Beijing, China, 1997.
- T. Yamada, “Hachimi-jio-gan,” in Kinki Youryaku, pp. 1–7, Kyouwa-Kikaku, Tokyo, Japan, 1992.
- T. Yokozawa, N. Yamabe, E. J. Cho, T. Nakagawa, and S. Oowada, “A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats,” Nephron Experimental Nephrology, vol. 97, no. 2, pp. e38–e48, 2004.
- T. Nakagawa, T. Yokozawa, N. Yamabe et al., “Long-term treatment with Hachimi-jio-gan attenuates kidney damage in spontaneously diabetic WBN/Kob rats,” Journal of Pharmacy and Pharmacology, vol. 57, no. 9, pp. 1205–1212, 2005.
- N. Yamabe and T. Yokozawa, “Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima Fatty rat: a model of human type 2 diabetes mellitus,” Journal of Pharmacy and Pharmacology, vol. 58, no. 4, pp. 535–545, 2006.
- N. Yamabe and T. Yokozawa, “Protective effect of Hachimi-jio-gan against the development of pancreatic fibrosis and oxidative damage in Otsuka Long-Evans Tokushima Fatty rats,” Journal of Ethnopharmacology, vol. 113, no. 1, pp. 91–99, 2007.
- Y. Sakagishi, “Total protein,” in Rinsho Kagaku Bunseki II, M. Saito, M. Kitamura, and M. Niwa, Eds., pp. 115–142, Tokyo Kagaku Dojin, Tokyo, Japan, 1968.
- S. F. Ali, C. P. LeBel, and S. C. Bondy, “Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity,” Neurotoxicology, vol. 13, no. 3, pp. 637–648, 1992.
- S. Komatsu, “Extraction of nuclear proteins,” Methods in Molecular Biology, vol. 355, pp. 73–77, 2007.
- J. Himmelfarb, P. Stenvinkel, T. A. Ikizler, and R. M. Hakim, “The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia,” Kidney International, vol. 62, no. 5, pp. 1524–1538, 2002.
- N. D. Vaziri, “Oxidative stress in uremia: nature, mechanisms, and potential consequences,” Seminars in Nephrology, vol. 24, no. 5, pp. 469–473, 2004.
- N. D. Vaziri, Y. Bai, Z. Ni, Y. Quiroz, R. Pandian, and B. Rodriguez-Iturbe, “Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction,” Journal of Pharmacology and Experimental Therapeutics, vol. 323, no. 1, pp. 85–93, 2007.
- H. J. Kim and N. D. Vaziri, “Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure,” American Journal of Physiology, vol. 298, no. 3, pp. F662–F671, 2010.
- K. Bedard and K. H. Krause, “The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology,” Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007.
- K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, “NAD(P)H oxidase: role in cardiovascular biology and disease,” Circulation Research, vol. 86, no. 5, pp. 494–501, 2000.
- G. Zalba, G. S. José, M. U. Moreno et al., “Oxidative stress in arterial hypertension: role of NAD(P)H oxidase,” Hypertension, vol. 38, no. 6, pp. 1395–1399, 2001.
- B. M. Babior, J. D. Lambeth, and W. Nauseef, “The neutrophil NADPH oxidase,” Archives of Biochemistry and Biophysics, vol. 397, no. 2, pp. 342–344, 2002.
- T. Etoh, T. Inoguchi, M. Kakimoto et al., “Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment,” Diabetologia, vol. 46, no. 10, pp. 1428–1437, 2003.
- T. Kawahara, D. Ritsick, G. Cheng, and J. D. Lambeth, “Point mutations in the proline-rich region of p22phox are dominant inhibitors of Nox1- and Nox2-dependent reactive oxygen generation,” Journal of Biological Chemistry, vol. 280, no. 36, pp. 31859–31869, 2005.
- R. J. McKallip, W. Jia, J. Schlomer, J. W. Warren, P. S. Nagarkatti, and M. Nagarkatti, “Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression,” Molecular Pharmacology, vol. 70, no. 3, pp. 897–908, 2006.
- K. I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, and M. Yamamoto, “Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model,” Molecular and Cellular Biology, vol. 26, no. 8, pp. 2887–2900, 2006.
- T. W. Kensler, N. Wakabayashi, and S. Biswal, “Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 89–116, 2007.
- C. J. Harvey, R. K. Thimmulappa, A. Singh et al., “Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress,” Free Radical Biology & Medicine, vol. 46, no. 4, pp. 443–453, 2009.
- W. Li and A. N. Kong, “Molecular mechanisms of Nrf2-mediated antioxidant response,” Molecular Carcinogenesis, vol. 48, no. 2, pp. 91–104, 2009.
- A. A. Anwar, F. Y. L. Li, D. S. Leake, T. Ishii, G. E. Mann, and R. C. M. Siow, “Induction of heme oxygenase 1 by moderately oxidized low-density lipoproteins in human vascular smooth muscle cells: role of mitogen-activated protein kinases and Nrf2,” Free Radical Biology & Medicine, vol. 39, no. 2, pp. 227–236, 2005.
- M. He, R. C. M. Siow, D. Sugden, L. Gao, X. Cheng, and G. E. Mann, “Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 4, pp. 277–285, 2011.
- Y. Hojo, Y. Saito, T. Tanimoto et al., “Fluid shear stress attenuates hydrogen peroxide-induced c-Jun NH2-terminal kinase activation via a glutathione reductase-mediated mechanism,” Circulation Research, vol. 91, no. 8, pp. 712–718, 2002.
- T. Kallunki, T. Deng, M. Hibi, and M. Karin, “c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions,” Cell, vol. 87, no. 5, pp. 929–939, 1996.
- S. Gupta, D. Campbell, B. Derijard, and R. J. Davis, “Transcription factor ATF2 regulation by the JNK signal transduction pathway,” Science, vol. 267, no. 5196, pp. 389–393, 1995.
- B. A. Hocevar, T. L. Brown, and P. H. Howe, “TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway,” The EMBO Journal, vol. 18, no. 5, pp. 1345–1356, 1999.
- P. A. Baeuerle and T. Henkel, “Function and activation of NF-κB in the immune system,” Annual Review of Immunology, vol. 12, pp. 141–179, 1994.
- C. Viedt, G. M. Hänsch, R. P. Brandes, W. Kübler, and J. Kreuzer, “The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-κB and AP-1,” The FASEB Journal, vol. 14, no. 15, pp. 2370–2372, 2000.
- Y. J. Surh, K. S. Chun, H. H. Cha et al., “Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation,” Mutation Research, vol. 480-481, pp. 243–268, 2001.
- F. Chow, E. Ozols, D. J. Nikolic-Paterson, R. C. Atkins, and G. H. Tesch, “Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury,” Kidney International, vol. 65, no. 1, pp. 116–128, 2004.
- T. Kosugi, T. Nakayama, M. Heinig et al., “Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice,” American Journal of Physiology, vol. 297, no. 2, pp. F481–F488, 2009.
- A. Sachse and G. Wolf, “Angiotensin II-induced reactive oxygen species and the kidney,” Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2439–2446, 2007.
- D. A. Allen, S. Harwood, M. Varagunam, M. J. Raftery, and M. M. Yaqoob, “High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases,” The FASEB Journal, vol. 17, no. 8, pp. 908–910, 2003.
- B. P. S. Kang, S. Frencher, V. Reddy, A. Kessler, A. Malhotra, and L. G. Meggs, “High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism,” American Journal of Physiology, vol. 284, no. 3, pp. F455–F466, 2003.
- M. L. Brezniceanu, F. Liu, C. C. Wei et al., “Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells,” Diabetes, vol. 57, no. 2, pp. 451–459, 2008.
- M. Crompton, “Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis,” Current Opinion in Cell Biology, vol. 12, no. 4, pp. 414–419, 2000.
- N. Kashihara, H. Sugiyama, and H. Makino, “Implication of apoptosis in progression of renal diseases,” Contributions to Nephrology, vol. 139, pp. 156–172, 2003.
- F. A. D. T. G. Wagener, D. Dekker, J. H. Berden, A. Scharstuhl, and J. van der Vlag, “The role of reactive oxygen species in apoptosis of the diabetic kidney,” Apoptosis, vol. 14, no. 12, pp. 1451–1458, 2009.
- G. Remuzzi, P. Ruggenenti, and A. Benigni, “Understanding the nature of renal disease progression,” Kidney International, vol. 51, no. 1, pp. 2–15, 1997.
- G. Remuzzi and T. Bertani, “Pathophysiology of progressive nephropathies,” New England Journal of Medicine, vol. 339, no. 20, pp. 1448–1456, 1998.
- B. M. Brenner, T. W. Meyer, and T. H. Hostetter, “Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease,” New England Journal of Medicine, vol. 307, no. 11, pp. 652–659, 1982.
- S. Bro, J. F. Bentzon, E. Falk, C. B. Andersen, K. Olgaard, and L. B. Nielsen, “Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2466–2474, 2003.
- T. Sakai, K. Kumano, S. Takara et al., “Effect of oral-adsorbent (AST-120) to chronic renal failure (CRF) in rats,” Japanese Journal of Nephrology, vol. 31, no. 4, pp. 359–365, 1989.
- M. Porkert, “Standards of value for phenomena of microcosmic dimensions I: orbisiconography,” in The Theoretical Foundations of Chinese Medicine, M. Porkert, Ed., pp. 107–196, The MIT Press, Cambridge, UK, 1978.